Latham Advises ATAI Life Sciences on US$125 Million Series C

^{Latham & Watkins advised ATAI Life Sciences, a global biotech platform, in raising US$125 million in a Series C financing round.}

^{The financing was led by Apeiron Investment Group, Peter Thiel and Catalio Capital Management.}

^{Proceeds from the financing will be used primarily to fund pre-clinical and clinical development of ATAI’s existing mental health programs, to expand its drug candidate pipeline and further advance ATAI’s platform technologies.}

^{The Latham team was led by London corporate partner Robbie McLaren and Frankfurt corporate partner Markus Krueger, with associates Jon Fox and David Funken.}